Neuroimmunology/Multiple sclerosis

Research group leader


  • PD Dr. med. Anke Salmen
  • PD Dr. med. Robert Hoepner
  • Dr. Vincent Pernet
  • PD Dr. med. Sandra Bigi
  • Dr. med. Nicole Kamber
  • Dr. med. Christoph Friedli
  • Dr. med. Helly Hammer
  • Dr. med. Lara Diem
  • Dr. med. Myriam Briner
  • Dr. med. Maximilian Pistor
  • Dr. Noemi Hiroshige (Study nurse)
  • Lea Weber (Study nurse)
  • Alisha Zmutt (Study nurse)
  • Besa Sylejmani (Study nurse intern)
  • Dr. Maud Bagnoud (Post doc)
  • Dr. Julius Baya Mdzomba (Post doc)
  • Ivo Meli (Research Assistant)
  • Jana Remlinger (PhD Student)
  • Sebastian Spiegel (PhD Student)
  • Victoria Lim Falk (PhD Student)
  • Marine Massy (Master Student)
  • Auste Asadauskas (Master Student)

Research focuses

  • Molecular surrogate marker/biomarker in neuroimmunological/neurodegenerative diseases
  • Therapy monitoring/risk stratification during therapy
  • Epidemiology, pharmacogenetics
  • Glial/neural immuno-biology
  • Animal models for degenerative diseases of the nervous system
  • Clinical studies
  • Disability measurement with modern para-clinical methods
  • Therapy studies


  • Murine animal model of MS: experimental autoimmune encephalomyelitis (EAE)
  • Experimental stroke (medial cerebral artery occlusion)
  • Histological and functional analyses in the context of animal models
  • Primary human cells and tissue/biological samples (peripheral immune cells, glial cells, CSF ): in vitro and ex vivo studies
  • Para-clinical/electrophysiological methods for detection of neurological disability in patients

Short description

The recently founded research group “Neuroimmunology/MS” combines basic research with translational and clinical approaches. We are particularly interested in the mechanisms of the autoimmune inflammatory responses of the nervous system in vitro, in animal models and in human biological samples with a special focus on glial and T-cell biology. The identification of potential molecular and clinical markers for detection of disease progression and the assessment of the benefit-risk profile under immunotherapy also follows a translational approach with biological samples from different clinical studies.